Kuvalanka Bolts Blueprint Medicines For COO Gig at Syros
Kyle Kuvalanka has been named the first chief operating officer of Cambridge, MA-based Syros Pharmaceuticals, a privately held startup developing so-called “gene control” drugs. Kuvalanka was previously the chief business officer of Blueprint Medicines (NASDAQ: BPMC), which went public and raised nearly $150 million in an IPO in April.
Underwriters and Partners
Xpertise: Watch + Learn
Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes
Sponsored · Whitepaper
Monitoring Solutions for Pharma-CRO/CMO Partnerships to Maintain Quality & Timelines
Implementing electronic solutions for risk mitigation
XiltriX
Sponsored · Whitepaper
Protecting Valuable Life Science Assets & Equipment: Monitoring Solutions
Remain compliant and ensure optimal productivity
XiltriX
From Our Advertisers
